A legacy that inspires the Future.
From the first guidewire to the first drug-eluting stent, Cordis has led cardiovascular innovation for over 60 years. Today, we're driving the next transformation through internal R&D, the Cordis-X incubator, and strategic acquisitions. Backed by a global footprint, we’re advancing technologies that improve outcomes, prioritize customer needs, and elevate education—reaffirming our commitment to the interventional community. Cordis will Go Beyond to transform cardiovascular care.
MYNX CONTROL VENOUS Vascular Closure Device
MYNX CONTROL VENOUS VCD is designed to pair procedural simplicity with enhanced safety & reliability, achieving rapid hemostasis*.
* Cordis 2024 Data on File.
MYNX CONTROL VENOUS Vascular Closure Device
VASSALLO GT Guidewire Portfolio
The VASSALLO® GT .014 and .018 Peripheral Guidewire Portfolio has been purposely engineered to deliver exceptional steerability, crossability and tip durability in simple to complex ATK and BTK cases.
SABER PTA Catheter Portfolio
The comprehensive SABER® PTA Dilatation Catheter Portfolio is engineered to provide exceptional crossability, deliverability, and a wide variety of sizes and shaft lengths, enabling physicians to treat a broad range of lesions from multiple access sites.
Radianz Radial Peripheral System
Representing a best-in-class radial offering from Cordis, the Radianz Radial Peripheral System™ is purposely engineered to deliver exceptional outcomes and a high level of patient satisfaction with products optimized for radial access and treatment–including the first and only stent indicated for iliac lesions.
RADIAL 360 Portfolio
From the proprietary KINK RECOVERY TECHNOLOGY™ of the RAIN Sheath® Transradial Thin-walled Introducer to the ZEPHYR® Vascular Compression Band that offers comfort, flexibility and patent hemostasis for radial closure, the RADIAL 360™ Portfolio offers the products you can depend on from access to closure.
Innovating and Delivering New Technologies
Cordis is proud to have completed the acquisition of Med Alliance and its novel SELUTION SLR™ Drug-Eluting Balloon (DEB). Using breakthrough proprietary technology, Med Alliance has found a unique solution to the challenge of controlled and sustained sirolimus release with the SELUTION SLR DEB. Cordis and Med Alliance combined are committed to accelerating the development and commercialization of innovative cardiovascular interventional products around the world.
The SELUTION SLR Drug-Eluting Balloon is not approved for sale in every country. Please contact your local representative for additional information
News
Driven by mission, guided by values
Cordis is making a difference. We impact millions of lives, in more than 60 countries around the world. We embrace a diverse, empowered culture where teammates are inspired to serve customers, patients and shareholders while fulfilling their own career aspirations.
Need Help?
We’re here with the support and information to help you make the right choices for your patients.